ARTICLE | Clinical News
NA-1: Ph III ESCAPE-NA-1 started
March 3, 2017 2:36 AM UTC
NoNo began the double-blind, placebo-controlled, international Phase III ESCAPE-NA-1 trial to evaluate 2.6 mg/kg IV NA-1 in about 1,120 patients who are candidates for endovascular revascularization....
BCIQ Company Profiles